[Induction chemotherapy in patients with head and neck cancer].
[Induction chemotherapy in patients with head and neck cancer].
复制标题
头颈癌患者的诱导化疗[J].
作者：
L. Chaigneau;E. Guardiola;Thierry N'guyen;A. Dufresne;U. Stein;C. Villanueva;A. Thiery;F. Lorchel;X. Pivot
新辅助化疗治疗晚期头颈部鳞状细胞癌已有20年的历史。尽管对原发性肿瘤具有高水平的活性，但没有研究表明使用新辅助化疗具有生存益处。可以认为，这种策略的唯一受益是可手术下咽癌或喉癌患者的喉保留。然而，最近，基于诱导化疗，随后根据放射治疗的活性的成熟保存策略已被Forastiere等人开发的使用主要伴随放化疗的策略推翻。然而，EORTC研究提供的最新结果阻碍了新辅助化疗报告的获益不足，该研究评估了紫杉醇-顺铂-氟尿嘧啶新辅助化疗的生存获益。有趣的是，自2002年以来，为晚期头颈癌患者制定的明确策略受到了挑战，新的选择正在出现。本文回顾了过去的标准策略和未来的建议出现在最近的研究。
Neoadjuvant chemotherapies for patients with advanced head and neck squamous cell carcinoma have been widely studied for twenty years. Despite a high level of activity on the primary tumor, no study has demonstrated a survival benefit suggesting the use of neoadjvant chemotherapy. One can consider that the only benefit of such strategy is for larynx preservation in patients with operable hypopharnx or larynx cancer. Nevertheless, recently the well established preservation strategy based on induction chemotherapy following according to the activity by radiotherapy has been knocked over by a strategy developed by Forastiere et al. using primary concomitant chemoradiotherapy. However, the lack of benefit reported by neoadjuvant chemotherapy has been thwarted by the recent results provided by the EORTC study which assessed the survival benefit of neoadjuvant chemotherapy by docetaxel-cisplatin-fluorouracile. Interestingly, since 2002 the clearly established strategies for patients with advanced head and neck cancer have been challenged and new options are emerging. This paper reviews the standard strategy of the past and the future proposal emerging from recent studies.